All posts by imreal

Technology: Electronics

Identify3D and Siemens Digital Industries Software sign OEM Partnership Agreement for Secure Digital Manufacturing Communication

Leave a comment



SAN FRANCISCO (PRWEB)

Identify3D, the leader in secure and standardized communication for digital manufacturing and 3D printing, today announced it has signed an original equipment manufacturer (OEM) partnership with Siemens Digital Industries Software, enabling an integrated solution of the Identify3D suite with NX™ software, the Teamcenter® portfolio and Siemens Opcenter™ software. Both companies can help customers support automated, end-to-end, secure and controllable manufacturing data distribution, collection and monitoring across multiple control systems and production equipment.

“Setting up and running an additive manufacturing factory should be as straightforward as connecting and using paper printers in the office. As soon as you plug a new printer into your network, your organization should be able to schedule and track jobs, securely send and collect data, and monitor performance,” comments Aaron Frankel, VP Additive Manufacturing Program, Siemens Digital Industries Software. “Together with Identify3D and our growing ecosystem of AM hardware OEMs, Siemens is helping enable our customers to securely connect, control, coordinate and monitor their entire global 3D printing and postprocessing operation.”

From NX, Teamcenter or Siemens Opcenter, customers can create encrypted data instructions for the operation of additive or subtractive machines. These “containers” of instructions include machine parameters, machine type, operator privileges, number of parts allowed, and more. Every action that affects a container for a given manufacturing operation can be collected, tracked and displayed in a dashboard for full visibility of the production process. Identify3D and Siemens have been working with leading 3D printer OEMs to develop integrated machine interfaces that fully support secure data transfer.

“Following a multiyear partnership with Siemens, we are very happy to make one further step towards a broader commercialization of our solution. We are very keen on bringing a key innovative addition to the Siemens Digital Industries Software portfolio and excited to support their global sales organization,” says Fabrizio De Pasquale, VP Business Development and Strategic Accounts at Identify3D. “Through a standardized data model and end-to-end integration, Siemens customers can lower operating costs by interacting more efficiently with machines. In addition, with secure data and enforceable process policies, they can realize more automated and regulated production both for in-house operations as well as for distributed scenarios.”

Share article on social media or email:

Society: Disabled Issues / Disabilities

God Is Our Source” is an illuminating collection of pages that supply daily help in the area of faith.

Leave a comment


News Image


MEADVILLE, Pa. (PRWEB)

“Daily Messages of Hope: God Is Our Source”: a brilliant medium of embracing the power of God through understanding His word that will help one get by day by day. “Daily Messages of Hope: God Is Our Source” is the creation of published author Mary Idella Criswell, a disabled homemaker who was an assistant director in the hospitality field. Because of an injury at work, she wasn’t able to continue working in 2002. Despite the incident, she’s happy to develop a closer relationship with her family. She joined the Powerhouse of Chicago in 2007 and she enjoys working in the pastoral care ministry to assist families.

Criswell shares, “Daily Messages of Hope is a book designed to provide scriptures that help us deal with daily problems that we encounter in our daily lives. It lets us know that God is our source. The scripture gives us insight on how to confront issues through the reading of God’s word. It will let us know that we all have a purpose in life. We all have gifts, but we must plow through the clutter in our lives to receive those gifts. We all need inspiration and motivation, which can be freely obtained through the reading of the Holy bible.

“By doing this, we can obtain the knowledge we need to survive in this world and prepare for eternal life. We need to rebirth new ideas through the power of God. We must give all our praise and worship to God, not man. I hope this book can provide some daily assistance in the area of faith. We all must maintain a healthy relationship with God, not just when we are in need. We need to listen and acknowledge God’s word. Through God, power and anointing those chains that have been keeping us in bondage can be broken. We just need to believe in him.”

Published by Christian Faith Publishing, Mary Idella Criswell’s new book is an important read that utilizes the Scripture in order to help any reader face their life’s daily problems and to trust in God that He can break any chains of struggle.

View a synopsis of “Daily Messages of Hope: God Is Our Source” on YouTube.

Consumers can purchase“Daily Messages of Hope: God Is Our Source” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Daily Messages of Hope: God Is Our Source,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Industry: Healthcare

Latest Regulatory Developments and Best Practices Webinar, Dec. 2, 2019

Leave a comment


WCG_FDANews_Logo

WCG_FDANews_Logo


FALLS CHURCH, Va. (PRWEB)

Understanding the Drug Supply Chain Security Act (DSCSA)

Latest Regulatory Developments and Best Practices

An FDAnews Webinar

Monday, Dec. 2, 2019, 1:30-3:00 p.m. EST

https://www.fdanews.com/understanding-the-dscsa

Need to comply with the Drug Supply Chain Security Act’s (DSCSA) implementation requirements? Is the company clear on nuances of the guidelines regulating the drug supply chain?

Don’t miss this webinar, including:

  • Key requirements under DSCSA

  • Reporting licensure

  • Knowing how to handle suspect and illegitimate products

  • Confirming authorized trading partners

  • How to comply with important guidances including FDA’s guidance on how to exchange product tracing information (DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information)

  • Who exactly is regulated under DSCSA, such as repackagers, wholesale distributors, dispensers and third-party logistics providers

  • What the most complicated and nuanced requirements are under DSCSA, such as product serialization and exchange of transaction information, transaction history and transaction statement

  • Which areas will be regulated soon under DSCSA, such as requirements for dispensers and distributors

  • How FDA is enforcing DSCSA, recent actions including warning letters


William Garvin, Esq. — a Buchanan Ingersoll & Rooney PC lawyer who assists clients daily in their interactions with FDA — will provide vital information to those involved in the manufacture, ownership, distribution or sale of prescriptions pharmaceuticals.

Gain the right tactics to avoid problems with DSCSA implementation.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Understanding the Drug Supply Chain Security Act (DSCSA)

Latest Regulatory Developments and Best Practices

An FDAnews Webinar

Monday, Dec. 2, 2019, 1:30-3:00 p.m. EST

https://www.fdanews.com/understanding-the-dscsa

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/understanding-the-dscsa

By phone: 888-838-5578 or 703-538-7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

Business: Executives

UCG Poised to Expand Marketing Prowess with Announcement of CMO

Leave a comment


“We feel that there is a new market era that is emerging, and we are proud to pair our proven manufacturing expertise with Jon’s rich background of marketing experience and network as we move into a more mature market phase,” said CEO Sushanta Parikh.


SANTA ROSA, Calif. (PRWEB)

Union Cannabis Group (UCG), a leading manufacturing and consulting company in the cannabis industry, is proud to announce its newest addition to the team, marketing expert Jon Bond.

Bond joins UCG as Chief Marketing Officer and brings over 30 years of experience as a thought leader and entrepreneur within the advertising and marketing industry. In addition to being the co-founder and CEO of KBP, Bond is currently chairman of Sito Mobile (NASDAQ), and has worked with numerous other key industry players including White Ops, Simplifi, Appinions, Blackbook Magazine, Klout, and Big Fuel (now Publicis).

Bond’s role with UCG will be to expand UCG’s product market share through the strategic implementation of new brands and resulting distribution channels. UCG currently has a secondary THC brand, a consumer product goods CBD brand, and a B2B CBD ingredient brand in development.

“UCG is primed to be a major player,” Bond said. “I am excited to help actualize the vision from a marketing and strategic relationship perspective.”

UCG is an expert in the fields of hydrocarbon and ethanol extraction, distillation, and product formulation. “It’s been a wild ride in the cannabis sector over the past couple of years,” said Sushanta Parikh, CEO of UCG. “We feel that there is a new market era that is emerging, and we are proud to pair our proven manufacturing expertise with Jon’s rich background of marketing experience and network as we move into a more mature market phase.”

UCG also owns and operates the award-winning brand Dabstract, a connoisseur recreational brand that is currently available throughout the state of Washington and is currently expanding to four additional states.

Bond is inspired by the quickly evolving pace of the cannabis industry. “I’m comfortable with change and chaos, which the industry has struggled through to this point. I will bring time tested approaches to the industry, and along with the rest of the UCG team will help steady the rudder in a turbulent sea.”

About UCG:

Union Cannabis Group, INC (UCG) offers design and installation services for cannabis extraction facilities, manufacturing process training, product formulation, and brand licensing. UCG serves clients in multiple states, with clients including Phat Panda (Grow Op Farms, LLC), Washington’s leading cannabis producer. UCG designed and currently operates their laboratory, which is the largest processing facility in the state. Dabstract, a premier brand of recreational cannabis extracts, is a wholly-owned subsidiary of UCG.

Share article on social media or email:

Health

Advanced Periodontics and Dental Implant Center of Connecticut Calms Dental Anxiety in Monroe, CT with Soothing Sedation Dentistry

Leave a comment


The Periodontists and Team at Advanced Periodontics and Dental Implant Center of Connecticut in Monroe, CT

Advanced Periodontics and Dental Implant Center of Connecticut Offers Sedation Dentistry Monroe, CT

I would recommend this practice to anyone. Dr. Amato really put me at ease. It was the best thing I ever did.


MONROE, Conn. (PRWEB)

Drs. Richard Amato and Michael Kang work to counter dental anxiety in Monroe, CT by offering sedation dentistry at their practice. Sedation dentistry helps make oral care simpler and more painless for patients. Drs. Amato and Kang have seen and treated countless patients whose severe dental anxiety has kept them from getting the oral health care they need, but who now keep coming back thanks to the warm atmosphere and sedation options provided at this state-of-the-art practice.

“I was having issues with my gums and I was afraid. Over time, my teeth were getting loose and I put it off out of fear. I used to have a lot of anxiety about going to the dentist and would not go, resulting in these gum disease problems,” says Christopher, a patient of Dr. Amato. “I would recommend this practice to anyone. Dr. Amato really put me at ease. It was the best thing I ever did.”

Sedation dentistry is an excellent solution for patients who experience mild to severe dental anxiety or fear. The practice offers oral sedation and nitrous oxide, as well as local anesthetic to help numb areas of the mouth where treatment will occur. Once a patient is sedated, they will feel calm, at ease and relaxed, but can still respond to the doctors if need be. This helps many patients receive their dental treatments, no matter how complex or extensive the need. In many cases, with the help of oral sedation or nitrous oxide, patients can have multiple treatments completed during one appointment, reducing the number of times they will need to visit the periodontists.

To supplement their calming sedation dentistry services, Drs. Amato and Kang offer modern, minimally invasive solutions for many dental treatments. The practice offers LANAP laser dentistry for treatment of gum disease without the need for scalpels or sutures, the Pinhole® Surgical Technique (PST™) for easy treatment of gum recession and full mouth dental implants as a more permanent and comfortable solution to complete tooth loss. For treatments like LANAP and PST, often minimal to no sedation is needed. Full mouth dental implant treatment always utilizes sedation dentistry and is typically completed in just one appointment, giving patients a brand-new set of teeth the same day.

In addition to sedation dentistry and minimally invasive care, Advanced Periodontics and Dental Implant Center of Connecticut offers comprehensive care from bone grafting, to periodontal maintenance and tooth extractions. The practice strives to stay up to date on the latest dental technology and trends, offering digital x-rays and 3D scanners. The doctors and team are compassionate, patient-centered and focused on providing lasting results.

Those interested in receiving gentle, pain-free dental care in Monroe, CT and surrounding areas are encouraged to connect with Drs. Amato and Kang to learn about their sedation dentistry options Consultations can be made by calling 203-268-2000 or visiting http://www.connecticutperiodontist.com.

About the Periodontists

Founder of Advanced Periodontics and Dental Implant Center of Connecticut in Monroe, Connecticut, Dr. Richard Amato, and his associate Dr. Michael Kang, are leading periodontists and dental implant specialists who offer personalized care using advanced technology. He earned his DDS degree from Stony Brook University and his Certificate of Proficiency in Periodontics from Eastman Dental Center at the University of Rochester. Dr. Amato has placed thousands of dental implants. He is the first and most experienced provider of LANAP® laser gum disease therapy in Fairfield County, CT as well as the first periodontist in Connecticut to provide the minimally invasive gum recession treatment, the Pinhole® Surgical Technique. Dr. Kang is a board-certified Diplomate of the American Academy of Periodontology. He completed his residency in periodontology from Columbia University and has published numerous articles on implant dentistry. To learn more about Dr. Amato, Dr. Kang or the services they offer visit http://www.connecticutperiodontist.com and call 203-268-2000.

Share article on social media or email:

Industry: Healthcare

EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems

Leave a comment



SEATTLE (PRWEB)

EMulate Therapeutics, Inc., a clinical-stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, announced it will have 5 poster presentations related to its medical devices for treating adult and pediatric brain cancers at the upcoming 24th Annual Society for Neuro-Oncology SNO Meeting in Phoenix, beginning on November 20 .

Two posters will be presented by Mike Butters, EMulate’s co-founder, at the affiliated SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS on Wednesday, November 20 at 5-7 pm. One poster describes the ability of the magnetic field of the device to penetrate the entire brain. The other poster provides early data to demonstrate that specific signals, referred to as cognates, can elicit differential behavioral responses in live animals.

Three poster presentations at the annual SNO meeting on Saturday, 23rd November, will provide updated data on the use of the Voyager ulRFE® system for treatment of patients with recurrent and newly diagnosed glioblastoma (GBM) and of the Hælo system to treat diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG).

The EMulate Voyager and Hælo systems appear to be safe for the treatment of adult and pediatric brain cancers; no serious device-related adverse events were reported. Additionally, the data from these feasibility studies suggest the EMulate Voyager and Hælo systems have clinical utility for the treatment of brain cancers and warrant further study in pivotal studies. Copies of the posters will be available at the EMulate exhibit table #312 at the SNO Conference.

Chris Rivera, EMulate Therapeutics President and Chief Executive Officer, made the announcement stating, “This year will mark our most active involvement in presenting clinical data and scientific technology regarding our proprietary Voyager and Hælo systems.”    

Rivera added “Our novel technology has the potential to transform the way we treat cancer. With these encouraging data in hand, we will continue to develop the EMulate Voyager system for the treatment of GBM and the Hælo system for the treatment of DMG/DIPG, with the aim to expand the underlying technology to additional indications in the future.”

Most recently, EMulate announced it had entered into an exclusive agreement for the distribution in India of the company’s proprietary systems for treatment of patients with selected brain cancer indications – both recurrent and newly diagnosed GBM and DMG/DPIG. The exclusive distributor is Sayre Therapeutics (Sayre), a Bangalore, India-based company that provides access to differentiated medical solutions to patients and clinicians in emerging markets by identifying high unmet needs across the healthcare continuum. The agreement with Sayre is EMulate’s second agreement with a highly-regarded international firm, the first being with Teijin Limited for the territory of Japan for the treatment of GBM.

EMulate will once again support the Annual SNO Conference at the Benefactor Sponsor Level.

About EMulate Therapeutics

Headquartered in Seattle, EMulate Therapeutics® is a clinical-stage therapeutic device company. EMulate has invented and patented a groundbreaking technology that utilizes precisely targeted ultra-low radio frequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-sterile, non-invasive, non-thermal, non-ionizing investigational device. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions as well as to veterinary medicine and non-medical applications. EMulate’s initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Pre-clinical work is focused on exploring new applications in oncology. In addition, EMulate’s Voyager system for adults with GBM and its Hӕlo pediatric system are investigational medical devices in clinical development.

Media Relations Contact:

Dennis Kroft

dkroft@emulatetx.com

201-602-8354

Share article on social media or email:

Business: Executives

Mohr Partners, Inc. Hires Patrick Hulsy as Managing Director in the Jersey City Office

Leave a comment



JERSEY CITY, N.J. (PRWEB)

Mohr Partners, Inc. the world’s largest wholly-owned commercial real estate advisory firm exclusively focused on representing tenants, today announced Patrick Hulsy has joined the firm as Managing Director, working directly with Managing Partner, Andrew Grabis.

Patrick will be responsible for developing new business and strategically servicing existing business for his clients that have international real estate portfolios. His extensive background as a results focused sales leader and strategic thinker with international experience will be a huge asset for Mohr Partners.

Prior to joining Mohr Partners, Patrick was a Senior Business Development Executive with Iron Mountain in New York. There, he cross-sold a host of information management and protection solutions to a book of 50 global firms, developed the largest pipeline on National Sales East team and identified $500,000 in previously undiscovered business.

Before that, Patrick was an Area Sales Manager for DHL Express where he recruited, developed and supported DHL’s Manhattan-based Sales Team, realized 40% book growth rate against a goal of 18% and sold close to $500,000 in new customer acquisition in one quarter against a goal of $125,000.

Mr. Hulsy holds a Bachelor in Foreign Services from Georgetown University’s A. Walsh School of Foreign Service and a Masters from Cornell University, School of Management.

About Mohr Partners, Inc.:

Mohr Partners, Inc. is a global corporate real estate advisor, providing corporate tenants with an integrated set of portfolio services including strategic planning, business intelligence, lease administration/accounting & FASB ASC 842 compliance, research and site selection, labor analytics, facility management, project & development, comprehensive demographics analysis, economic incentives negotiations and transaction management. Since 1986, Mohr has been managing real estate portfolios for corporations, and each year completes transactions for its clients in all 50 U.S. states, all provinces of Canada and locations around the world. Mohr seamlessly provides corporate real estate services globally through its strategic alliance partners in Canada, Mexico/Latin America, EMEA and the Asia Pacific. For more information on Mohr, please visit http://www.mohrpartners.com.

For more information contact:

Andrew Grabis

Managing Partner

908 672 3371

andy.grabis@mohrpartners.com

Share article on social media or email:

Health

Bioclinica Medical Imaging Achieves Milestone with Celebration of Primary Endpoint Data Analysis Contributions to 200 FDA Approvals

Leave a comment


News Image

“At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people’s lives,” said David Herron, President & CEO of Bioclinica.


PRINCETON, N.J. (PRWEB)

Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company’s history: the company has contributed reliable data to the primary efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. Food and Drug Administration.

“At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people’s lives,” said David Herron, President & CEO of Bioclinica. “We are grateful to our scientific and project teams, and to all the patients and their families who participated in the clinical studies.”

Bioclinica provides science and technology expertise to assist the life science industry in advancing the development of medical therapies through services in Medical Imaging, Drug Safety Solutions, and Software Solutions. Bioclinica Medical Imaging provides comprehensive support across multiple therapeutic areas, with particular expertise in oncology, musculoskeletal, cardiovascular, gastrointestinal, neuroscience, endocrinology, infectious and respiratory disease.

“Every day, Bioclinica’s team of professionals works to ensure the quality and integrity of the data we process, ensuring that our clients and regulatory authorities have information they can rely upon to evaluate the safety and efficacy of investigational treatments,” said Todd Kisner, Senior Vice President, Quality Assurance & Regulatory Compliance. “We look forward to continuing to partner with the biopharmaceutical industry as the pace of innovation accelerates and the demand for high-quality image and clinical data analysis combined with regulatory expertise increases.”

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company’s offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company’s thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

Learn more about Bioclinica at http://www.Bioclinica.com. Follow the latest company news and happenings on LinkedIn and Twitter.

Share article on social media or email:



Industry: Healthcare

Colic Calm® Launches Colic Calm Probiotic – a new product for the digestive wellness of infants

Leave a comment



SARASOTA, Fla. (PRWEB)

Colic Calm, the leading effective natural solution for infant digestive discomfort, has just announced the launch of their specially formulated five-strain probiotic with guaranteed live active cultures and 5 billion CFU per serving. Colic Calm and Colic Calm Plus have been a trusted companion for many moms with infants who struggle with colic, gas, and reflux. With the launch of the Colic Calm Probiotic, many parents may find continued relief and support of infant and child gut and digestive health.

Building a healthy microbiome is critical in the very early days to establish a healthy immune system, which not only prevents serious infections but is also thought to help prevent things like allergies, eczema, asthma, autoimmune conditions like type 1 diabetes, and even neurodevelopmental issues like autism and ADHD. The demand for safe, effective and living probiotics prompted Colic Calm to create a five-strain formulation with specific probiotics known to support digestive health. Colic Calm Probiotic comes as a one-time prep kit and includes a sachet of probiotics, a one-time use funnel, a bottle of MCT oil and a syringe.

“As leaders in infant gut health, we understand how important it is to have “good bacteria” to start your baby’s digestive system off right. We wanted to create a probiotic that had guaranteed live cultures, the most effective probiotic strains available and the highest CFU count per serving and is also free from sugar, gluten, wheat, soy, dairy and animal products,” said Keith Page, CEO of Colic Calm. “Colic Calm Probiotics are safe, gentle, and intended for everyday use.”

Since it was founded, Colic Calm has been dedicated to providing babies and parents with the highest-quality remedy for colic, gas and reflux. Now with the launch of the Colic Calm Probiotic, moms can trust they will receive the same quality and effectiveness that they’ve come to depend on with Colic Calm and Colic Calm Plus. Available nationally at Buy Buy Baby, Colic Calm Probiotic is also available online at Amazon.com, Walmart.com and ColicCalm.com with a suggested retail price of $19.95.

About Colic Calm

Colic Calm is the leader in effective natural solutions for infant digestive discomfort. From the start, Colic Calm has made it their mission to develop innovative, effective and natural wellness solutions. All products are made with the highest quality natural ingredients to empower families to be their best, and healthiest selves. Colic Calm, Colic Calm Plus and Colic Calm Probiotic provide effective relief without relying on synthetic-laden formulations.

For more information contact:

Anna Chase, Director of Marketing & Digital

US: +1 941 202 4802

E: anna@ketomi.com

Share article on social media or email:

Business: Executives

Retail Gift Card Association Announces 2019-2020 Board of Directors

Leave a comment


News Image

“Our newly formed board is full of well-established and respected industry trailblazers and will help us to grow our association as an even stronger voice for closed-loop gift cards.


MINNEAPOLIS (PRWEB)

Today the Retail Gift Card Association (RGCA) announced its 2019-2020 leadership, including new board members and the appointment of two current board members to executive-level positions.

Founded in 2008, the Retail Gift Card Association is a trade association of more than 100 diverse, closed-loop gift card retailers and non-retailer supporting members committed to promoting and protecting the use of gift cards. Members collectively fuel consumer confidence in the industry, evolve best practices for gift card programs and optimize emerging opportunities to meet demand for digital payments and contextual commerce.

Effective immediately, the 2019-2020 RGCA board of directors includes the following new and returning members:


  • Chair: Erin Wood, Subway® Restaurants

  • Vice Chair: Ken Bott, Darden Restaurants

  • Treasurer: Lesa Hernandez, GameStop

  • Chair Emeritus: Nathan Ehrlich, The Home Depot

  • Colleen Dorwart, Travel Tags

  • Kevin Halvorsen, Macy’s

  • Krista Lee, Fiserv

  • Laura Parker, Best Buy

  • Jen Porras, Brinker International

  • Ryan Post, Starbucks

  • Chet Putnam, Walmart

  • Kim Sobasky, Inspire Brands

  • Abby Teigland, AMC Theatres

  • Jeff Weatherly, Optimum Card Solutions

  • Alternate: Alex Barseghian, Blackhawk Network

  • Alternate: Kathy Cook, DSW

  • Alternate: Jeff Hood, Zaxby’s

  • Alternate: Martha Weaver, Raise

“It is an exciting time to be involved with the RGCA, as consumers and businesses are quickly evolving the way they use gift cards as stored value payments tools—and no longer just as gifting options,” said Erin Wood, RGCA Board Chair. “Our newly formed board is full of well-established and respected industry trailblazers and will help us to grow our association as an even stronger voice for closed-loop gift cards. I am invigorated to work with the new RGCA leadership team to propel our association toward continued success in the future.”

The RGCA board of directors thanks former board members for their unwavering support and commitment while serving on the board.

  • Tim Anderson, AMC Theatres

  • Michelle Brown

  • Andy Choi, The Walt Disney Company

  • Nicole Glass, Gift Card Impressions

  • Marina Hodges, Blackhawk Network (formerly with Walmart)

  • Jayne Stegemiller, Zaxby’s

For more information, including details on becoming a member, visit theRGCA.org.

About the Retail Gift Card Association (RGCA)

The Retail Gift Card Association is the nonprofit trade association that represents the closed-loop gift category. The Association’s mission is to protect, promote and enhance the use of retail gift cards as forms of branded currency and stored value solutions that enable, enrich, and encourage commerce in today’s digital age. All RGCA members abide by a Code of Principles that supports consumer-friendly policies for the purchase and redemption of closed-loop gift cards. RGCA’s membership is comprised of retailers from all sectors, including restaurants, general merchandise, apparel, sporting and leisure, and non-retailers. For more information, visit us at thergca.org.

Share article on social media or email: